Immune Checkpoint Blockade in Triple Negative Breast Cancer Influenced by B Cells through Myeloid-Derived Suppressor Cells

Researchers showed that a combination immunotherapy platform utilizing low dose chemotherapy combined with oncolytic virotherapy increased tumor-infiltrating lymphocytes, in otherwise immune-bare tumors, allowing 60% of mice to achieve durable tumor regression when treated with immune checkpoint blockade.